Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer

NCT01145404 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

76

Enrollment

OTHER

Sponsor class

Stopped Changes of SoC for third line therapy resulting in poor recruitment

Conditions

GastroEsophageal Cancer

Interventions

DRUG: Lapatinib
DRUG: Lapatinib plus capecitabine

Sponsor

National Center for Tumor Diseases, Heidelberg